Press Release FeedGet the RSS feed
Menu

Browse press releases

The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.

1,636 resultsPage 11 of 137, newest first
  1. HealthcareOrum Therapeutics Doses First Patient in Phase 1 Trial of ORM-1153, a CD123-GSPT1 Degrader-Antibody ConjugateOrum announced that the first patient has been dosed in a Phase 1 clinical trial evaluating ORM-1153, the Company’s investigational CD123-GSPT1 DAC.
  2. FinanceGOA Therapeutics CorporationSEC Qualifies GOA Therapeutics’ Public Offering to Sell Up to $300 Million in Stock; Set for Launch October 15Financing strategy is designed to advance GOA26, a first-in-class drug candidate for the treatment of acute alcohol intoxication and poisoning
  3. FinanceLiquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAHLiquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced that it has entered into a global settlement agreement with United Therapeutics Corporation (Nasdaq: UTHR) that resolves all pending litigation between the companies. Importantly, YUTREPIA® (treprostinil) inhalation powder will remain available to patients with PAH without disruption.
  4. FinanceINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACADPomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
  5. AIGenerate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic DiseasesCollaboration will combine Zealand Pharma’s expertise in metabolic health with Generate’s proprietary generative AI platform to create multispecific drug candidates with tailored biological functions
  6. AIZealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic DiseasesPress release – No. 20 / 2026
  7. AISuvoda LLCSuvoda makes Sofia AI assistant available for clinical trials to drive faster answers and actionKey Takeaways Clinical trials require guard railed AI that's purpose built for the regulated industry that has high human stakes and required audit trails. Sofia helps make complex, fast-moving trial data more accessible to study teams who manage large volumes of time-sensitive work. Study teams can get faster answers and take confident action. Sofia goes beyond information retrieval and can execute authorized system
  8. FinanceGlobal In Vivo Cell Therapy Market Size, Share, Trends, and Forecast, 2026-2033 | Targeted Delivery and Cell Engineering Drive 49.6% CAGR Toward USD 5.72 BillionTarget North America and invest in targeted delivery and programmable cell-engineering to unlock new revenue streams in precision medicine.
  9. HealthcareTreasure Global Signs MOU to Expand Medical Supply and Pharmaceutical Distribution Across Southeast AsiaCollaboration Targets Government and Institutional Procurement with Six-Month Exclusivity
  10. FinanceAlaunos Therapeutics Announces Acquisition of Velaris TherapeuticsAcquisition of Velaris and concurrent oversubscribed $350 million private placement positions the Company to deliver multiple proof-of-concept datasets in pulmonary arterial hypertension
  11. Biotech & pharmaNuravax, Inc.Nuravax and Institute for Molecular Medicine Announce Publication of Phase 1 Results for AV-1959R Amyloid-Beta VaccineRandomized, placebo-controlled study in 16 cognitively unimpaired participants met safety and immunogenicity objectives; all 12 vaccine recipients developed anti-Aβ antibodies after two priming doses Randomized, double-blind, placebo-controlled Phase 1 trial enrolled 16 cognitively...
  12. FinanceMBX Biosciences, Inc.MBX Biosciences to Participate in Upcoming November Investor ConferencesMBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Steve Hoerter, Chairman and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present at, and participate in, the following upcoming investor conferences: